Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
TARGETED ONCOLOGY THERAPIES - Harnessing Nature’s “Cues” to Selectively Activate the Immune System to Attack Cancer November 29, 2021
Dan Passeri, MSc, JD, reviews a new class of synthetic biologic drugs engineered and designed to leverage the beneficial effect of IL-2 to selectively stimulate the proliferation and cytotoxic activity of disease-relevant T cells against cancer.
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics August 17, 2021
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
EXECUTIVE INTERVIEW - Pace Analytical® Life Sciences: Delivering Science Better; Advancing Novel Therapies Through the Clinic to Commercialization March 1, 2021
Frank Tagliaferri, PhD, Vice President of Pharmaceutical Development at PLS, discusses his experiences with the company and its recent growth.
Exelixis & Catalent Enter Collaboration, License & Exclusive Option Agreement September 9, 2020
Exelixis, Inc. and Catalent recently announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for….
NEXT-GENERATION TUMOR TARGETING - Leveraging the Tumor Microenvironment to Change the Standard of Care June 4, 2020
Vishwas Paralkar, PhD, highlights a unique platform technology that represents the first technology that has successfully been used to target cancer drugs to tumor cells in animal models, while sparing healthy tissue.
Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial May 19, 2020
Triphase Accelerator and Catalent recently announced interim results for Triphase Accelerator's multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated...Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept January 30, 2020
Avacta Group plc recently announced it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in...White Paper: Control of Beta-Glucans & Endotoxin in High Purity Sucrose for Biopharmaceutical Applications October 16, 2019
This white paper discusses a Quality by Design (QbD) scenario that allows end users to rationally select the well characterized excipients during biopharmaceutical development and develop a control strategy for biologic drug products.
Catalent Completes Acquisition of Gene Therapy Leader for $1.2 Billion May 23, 2019
Catalent, Inc. recently announced it has completed the $1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and...Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma April 3, 2019
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the...Avacta Group Announces Positive Outcome of Proof-of-Concept Study January 23, 2018
Avacta Group plc recently announced its initial study with Glythera Limited, the developer of next-generation antibody drug conjugates, has concluded...Daiichi Sankyo Announces Multi-Billion Manufacturing Investment May 4, 2017
Daiichi Sankyo Company, Limited recently announced it is making an initial 15 billion yen investment to optimize and enhance its...SPECIAL FEATURE - Analytical Testing: Market Drivers, Growing Demand & Client Needs January 17, 2017
Contributor Cindy H. Dubin spoke with several testing providers to find out what services they offer, trends they identify, and how they have specifically addressed clients’ needs throughout the past year.
Catalent Biologics & Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag October 11, 2016
Catalent and Triphase Accelerator Corporation recently announced that Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug...Piramal Enterprises Enters Agreement to acquire Ash Stevens August 23, 2016
Piramal Enterprises Limited recently announced that its wholly owned subsidiary in the US has entered into an agreement to acquire...Oncternal Therapeutics Merges With Tokalas to Form Clinical-Stage Biotechnology Company June 6, 2016
Oncternal Therapeutics, Inc. and Tokalas, Inc., recently announced the two companies have completed a merger to create a new world-class...SPECIAL FEATURE - Excipients: Manufacturers Look to Co-Processing as a Way of Improving Functionality June 2, 2016
Contributor Cindy H. Dubin reports how leading excipient manufacturers are overcoming their own R&D challenges to deliver innovative excipients that address problems associated with both large and small molecules.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Biologics Present a New Set of Challenges May 2, 2016
Contributor Cindy H. Dubin speaks with leading syringe developers and contract manufacturers to discuss how they are overcoming industry challenges and provides a look at some of the innovative advancements in prefilled syringe technology.
Trehalose: A Powerful Excipient in the Formulation Toolbox June 11, 2015
By: Ben Nelson, PhD, and Chris Wilcox (inquiries to: cs@pfanstiehl.com) Trehalose is a non-reducing disaccharide consisting of two glucose...Oxford BioTherapeutics Grants Exclusive License to Boehringer Ingelheim January 19, 2015
Oxford BioTherapeutics recently announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from...
